<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31074">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02702180</url>
  </required_header>
  <id_info>
    <org_study_id>MOL-PAP-002</org_study_id>
    <nct_id>NCT02702180</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)</brief_title>
  <acronym>IMPALA</acronym>
  <official_title>A Randomised, Double-Blind, Placebo-Controlled Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary AlveoLAr Proteinosis Patients &quot;IMPALA&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Savara Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Savara Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates inhaled molgramostim (recombinant human (rh) Granulocyte
      Macrophage-Colony Stimulating Factor (GM-CSF)) in the treatment of autoimmune pulmonary
      alveolar proteinosis patients. A third of the patients will receive inhaled molgramostim
      daily for 24 weeks, a third will receive inhaled molgramostim every other day for 24 weeks
      and a third will receive inhaled matching placebo for 24 weeks
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial is a randomised, double-blind, placebo-controlled multicentre clinical trial
      investigating efficacy and safety of inhaled molgramostim (rhGM-CSF) in autoimmune pulmonary
      alveolar proteinosis (aPAP) patients.

      The primary objective is efficacy on the Alveolar-arterial oxygen difference after 24-weeks
      treatment. Secondary objectives are requirement for, and time to, Whole Lung Lavage (WLL),
      effect on pulmonary function, tolerance to exercise, effect on dyspnea, cough and Quality of
      Life, and effect on computed tomography (CT) scoring. Number of reported adverse events
      (AEs), serious AEs, and adverse drug reactions will be monitored.

      The trial will include two phases; a Double-blind treatment period consisting of up to eight
      trial visits (Screening, Baseline, and at Weeks 4,8,12, 16, 20 and 24 after randomisation)
      and a Follow-up period consisting of up to five trial visits (at Weeks 4, 12, 24, 36 and 48
      post-treatment).

      In the Double-blind treatment period, eligible subjects will be randomised to treatment for
      up to 24 weeks with either: 1) inhaled molgramostim (300 µg) once daily, 2) inhaled
      molgramostim (300 µg) and matching placebo administered intermittently (seven days on and
      seven days off) or 3) inhaled placebo once daily. During the Double-blind treatment period,
      WLL may be applied as rescue therapy in case of significant clinical worsening.

      Brief risk assessment:

      There is currently no approved pharmacological treatment for patients with PAP, and
      therefore an unmet need for further treatment modalities exists.

      Results from pre-clinical studies with inhaled molgramostim nebuliser solution showed the
      expected pharmacological effects on white blood cell (WBC) populations locally and
      systemically in line with observed effects after IV administration of molgramostim. No
      severe, serious or dose-limiting AEs were observed in the first clinical study in humans
      (MOL-001). The most common AE was cough, which was reported at a similar incidence for the
      molgramostim nebuliser solution and placebo. Increases of WBC populations in the blood
      consistent with the known mechanism of action were observed; most of which were considered
      not clinically significant. Only two cases (total WBC increased and eosinophilia) were
      reported as AEs. No development of anti-drug antibodies was observed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change from baseline to 24 weeks of Alveolar - arterial oxygen concentration (A-a(DO2))</measure>
    <time_frame>baseline and 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects in need of Whole Lung Lavage (WLL)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to WLL</measure>
    <time_frame>during 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline to 24 weeks in Vital Capacity (% predicted)</measure>
    <time_frame>baseline and 24 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline to 24 weeks in pulmonary function tests</measure>
    <time_frame>baseline and 24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline to 24 weeks in 6 minute walk distance</measure>
    <time_frame>baseline and 24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline to 24 weeks in dyspnoea score</measure>
    <time_frame>baseline and 24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline to 24 weeks in cough score</measure>
    <time_frame>baseline and 24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline to 24 weeks in Quality of Life scores</measure>
    <time_frame>baseline and 24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of treatment-emergent adverse events (AEs), serious AEs, Adverse Drug Reactions and Severe AEs</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Autoimmune Pulmonary Alveolar Proteinosis</condition>
  <arm_group>
    <arm_group_label>molgramostim continuously</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhalation of molgramostim nebuliser solution (rhGM-CSF) 300 mcg once daily for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>molgramostim intermittently</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhalation of molgramostim nebuliser solution (rhGM-CSF) 300 mcg every other day and placebo nebuliser solution every other day for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inhalation of placebo nebuliser solution once daily for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>molgramostim</intervention_name>
    <description>molgramostim nebuliser solution</description>
    <arm_group_label>molgramostim continuously</arm_group_label>
    <arm_group_label>molgramostim intermittently</arm_group_label>
    <other_name>rhGM-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo nebuliser solution</description>
    <arm_group_label>molgramostim intermittently</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aPAP diagnosed by computed tomography, or by biopsy, or by Broncho Alveolar Lavage
             (BAL), and by increased GM-CSF autoantibodies in serum.

          -  Stable or progressive aPAP during a minimum period of two months prior to the
             Baseline visit.

          -  Arterial oxygen concentration &lt;75 mmHg/&lt;10 kilo Pascal (kPa) at rest, OR desaturation
             of &gt;4 percentage points on the 6 Minute Walk Test (6MWT)

          -  An (A-a)DO2 of minimum 25 mmHg/3.33 kPa

          -  Female or male ≥18 years of age

          -  Females who have been post-menopausal for &gt;1 year or females of childbearing
             potential after a confirmed menstrual period using a highly efficient method of
             contraception (i.e. a method with &lt;1% failure rate such as combined hormonal
             contraception, progesterone-only hormonal contraception, intrauterine device,
             intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised
             partner, sexual abstinence), during and until 30 days after last dose of double-blind
             trial treatment. Females of childbearing potential must have a negative serum
             pregnancy test at Screening (Visit 1) and a negative urine pregnancy test at dosing
             at Baseline (Visit 2) and must not be lactating

          -  Males agreeing to use condoms during and until 30 days after last dose of
             double-blind medication, or males having a female partner who is using adequate
             contraception as described above

          -  Willing and able to provide signed informed consent

          -  Willing and able to comply with scheduled visits, treatment plan, laboratory tests,
             and other trial procedures specified in the protocol as judged by the investigator

        Exclusion Criteria:

          -  Diagnosis of hereditary or secondary pulmonary alveolar proteinosis (PAP)

          -  WLL within two months of Baseline

          -  Treatment with GM-CSF within three months of Baseline

          -  Treatment with rituximab within six months of Baseline

          -  Treatment with plasmapheresis within three months of Baseline

          -  Treatment with any investigational medicinal product within four weeks of Screening

          -  Concomitant use of sputum modifying drugs such as carbocysteine or ambroxol

          -  History of allergic reactions to GM-CSF

          -  Connective tissue disease, inflammatory bowel disease or other autoimmune disorder
             requiring treatment associated with significant immunosuppression, e.g. more than 10
             mg/day systemic prednisolone

          -  Previous experience of severe and unexplained side-effects during aerosol delivery of
             any kind of medicinal product

          -  History of, or present, myeloproliferative disease or leukaemia

          -  Significant liver impairment (aspartate aminotransferase (AST) or alanine
             aminotransferase (ALT) level &gt;4 times the upper normal limit) or renal impairment
             (estimated Glomerular Filtration Rate (eGFR) &lt;30 mL/min/1.73m2) at Screening.

          -  Known active infection (viral, bacterial, fungal or mycobacterial)

          -  Apparent pre-existing concurrent pulmonary fibrosis

          -  Any other serious medical condition which in the opinion of the investigator would
             make the subject unsuitable for the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cliff Morgan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Brompton Hospital London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica Jackson</last_name>
    <email>jessica.jackson@savarapharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cecilia Ganslandt, MD</last_name>
    <email>cega@savarapharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth Bendstrup, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Elisabeth Bendstrup, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rennes Hospital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephane Jouneau, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stephane Jouneau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westdeutsches Lungenzentrum am Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Bonella, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Bonella</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Fachkliniken München - Gauting</name>
      <address>
        <city>Gauting</city>
        <zip>82131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wolfgang Gesierich, MD</last_name>
    </contact>
    <investigator>
      <last_name>Wolfgang Gesierich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juliane Herpich, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik am Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Hummler, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michael Kreuter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simone Hummler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg/Saar</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Faehndrich, MD</last_name>
    </contact>
    <investigator>
      <last_name>Robert Bals, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sebastian Faehndrich, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Attikon University Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Effrosyni Manali, MD</last_name>
    </contact>
    <investigator>
      <last_name>Spyros Papiris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Beilinson</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mordechai R Kremer, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mordechai R Kremer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wand Ori, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilaria Campo, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Francesca Mariani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Makoto Kobayashi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Makoto Kobayashi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aichi Medical University Hospital</name>
      <address>
        <city>Nagakute</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etsuro Yamaguchi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Etsuro Yamaguchi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Niigata University Medical and Dental Hospital</name>
      <address>
        <city>Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryushi Tazawa, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ryushi Tazawa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kinki-Chuo</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoshikazu Inoue, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yoshikazu Inoue</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cardiovascular and Respiratory Center</name>
      <address>
        <city>Yokohama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baba Tomohisa, MD</last_name>
    </contact>
    <investigator>
      <last_name>Baba Tomohisa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcel Veltkamp, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marcel Veltkamp, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City Hospital St. Petersburg</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yulia Ilkovich, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Yulia Ilkovich, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital University de Bellvitge (HUB)</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Molina Molina, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maria Molina Molina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romain Lazor, MD</last_name>
    </contact>
    <investigator>
      <last_name>Romain Lazor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cliff Morgan, MD</last_name>
    </contact>
    <investigator>
      <last_name>Cliff Morgan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://savarapharma.com/</url>
    <description>Savara homepage (Sponsor)</description>
  </link>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 20, 2017</lastchanged_date>
  <firstreceived_date>February 28, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pulmonary Alveolar Proteinosis</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Molgramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
